The Recall Desk

Severity 4 of 5

Severe recalls

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

What “severe” means here

Severity 4 (Severe) recalls have a real, documented risk of significant injury, hospitalization, or property damage even if no deaths have been reported. The agency classification is FDA Class II with hospitalization reports, USDA Class I, or a structural vehicle defect. These need attention quickly — not five-alarm urgency but not something to put off. Examples include allergen mislabeling on common allergens for products eaten by children, drug potency out of specification by a margin that could cause measurable harm, and vehicle defects affecting braking or steering.

The full rubric is on the methodology page. Severity is computed deterministically from the agency’s own classification plus the source text — no editorial vibes.

23376–23400 of 32176

  • SevereFDA (Drugs)·D-815-2015·2015-04-29

    Attix Pharmaceuticals Recalls Neostigmine Methylsulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Neostigmine Methylsulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Neostigmine Methylsulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-712-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrochlorothiazide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydrochlorothiazide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydrochlorothiazide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-788-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methscopolamine Bromide Combo active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-638-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dopamine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dopamine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dopamine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-725-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyoscine Butylbromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hyoscine Butylbromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hyoscine Butylbromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-554-2015·2015-04-29

    Cabergoline API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Cabergoline active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cabergoline active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-763-2015·2015-04-29

    Lincomycin HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Lincomycin HCl Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Lincomycin HCl Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-530-2015·2015-04-29

    Avanafil API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling all lots of Avanafil active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Avanafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-575-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloramphenicol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloramphenicol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Chloramphenicol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-517-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amlodipine Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Amlodipine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amlodipine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-698-2015·2015-04-29

    Gefitinib API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Gefitinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Gefitinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-572-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cephalexin Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cephalexin Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cephalexin Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-837-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pergolide Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pergolide Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pergolide Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-793-2015·2015-04-29

    Attix Pharmaceuticals Recalls Metronidazole Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Metronidazole Base active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Metronidazole Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-931-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tizanidine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tizanidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tizanidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-594-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clomiphene Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clomiphene Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clomiphene Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-713-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrocortisone Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling hydrocortisone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydrocortisone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-823-2015·2015-04-29

    Attix Pharmaceuticals Recalls Omeprazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Omeprazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Omeprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-658-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estrone API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estrone active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Estrone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-508-2015·2015-04-29

    Alpha Chymotrypsin Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Alpha Chymotrypsin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Alpha Chymotrypsin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-864-2015·2015-04-29

    Attix Pharmaceuticals Recalls Procaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Procaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Procaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-948-2015·2015-04-29

    Valacyclovir HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Valacyclovir HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Valacyclovir HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-686-2015·2015-04-29

    Fluphenazine HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluphenazine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Fluphenazine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-766-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lisinopril Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Lisinopril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Lisinopril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-573-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cetirizine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cetirizine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Cetirizine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide